

# EFFECTIVENESS OF FIXED-DOSE COMBINATION STAVUDINE, LAMIVUDINE AND NEVIRAPINE (GPO-VIR) FOR TREATMENT OF NAÏVE HIV PATIENTS IN THAILAND: A 3-YEAR FOLLOW-UP

Varunee Desakorn<sup>1</sup>, Biraj Man Karmacharya<sup>1</sup>, Vipa Thanachartwet<sup>1</sup>, Nyan Lin Kyaw<sup>1</sup>, Somsit Tansuphaswadikul<sup>2</sup>, Duangjai Sahassananda<sup>3</sup>, Jittima Dhitavat<sup>1</sup>, Wirach Maek-a-nantawat<sup>1</sup> and Punnee Pitisuttithum<sup>1</sup>

<sup>1</sup>Department of Clinical Tropical Medicine; <sup>3</sup>Information Technology Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok; <sup>2</sup>Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand

**Abstract.** Generic fixed dose combination stavudine (d4T), lamivudine (3TC) and nevirapine (NVP), named GPO-VIR is recommended in the HIV treatment guidelines for Thailand. The long term effectiveness and adverse effects of this drug combination for the treatment of HIV were evaluated in an ambispective study at Bamrasnaradura Infectious Diseases Institute, Nonthaburi Province, Thailand from March 2002 to January 2006. A total of 152 adult treatment naïve HIV patients who had received at least 12 months of GPO-VIR were enrolled. The median (IQR) CD4 cell count increased from 23 (8-94) cells/ l at baseline to 126 (38-180), 136 (98-189), 199 (141-255) and 334 (243-414) cells/ l at 3, 6, 12 and 24 months ( $p<0.001$ ), respectively. The median (IQR) percentage of body weights increased from baseline by 3.0% (0.3-6.3), 6.2% (2.2-9.3), 7.3% (3.9-10.9) and 8.1% (3.4-11.9) at 3, 6, 12 and 24 months, respectively and then remained at a plateau until the end of the 3-year study. The occurrence of new opportunistic infections decreased significantly ( $p<0.001$ ) with GPO-VIR treatment. Drug resistance occurred in 5 cases (3.3%) with a median (IQR) time of 18.0 (16.5-32.5) months to occurrence. Adverse effects included hypercholesterolemia (43.2%), lipodystrophy (35.5%), hypertriglyceridemia (25%), hypertension (13.1%), peripheral neuropathy (11.9%), hyperlactatemia (2.6%) and lactic acidosis (1.3%). Thirty-six patients (27%) switched from GPO-VIR to other anti-retroviral drugs regimens due to lipodystrophy. This study showed GPO-VIR had clinical and immunological benefits, but one-third of patients had adverse effects.

**Keywords:** HIV, GPO-VIR, effectiveness, adverse effect, CD4 count

---

Correspondence: Dr Punnee Pitisuttithum, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Bangkok 10400, Thailand.  
Tel: +66 (0) 2643 5597; Fax: +66 (0) 2643 5598  
E-mail: tmppt@mahidol.ac.th